The impact of SF3B1 mutations on patient outcomes varies according to tumor type; for instance, it is associated with poor outcomes in CLL patients but with good prognoses in uveal melanoma patients [8, 11, 18–20]. Here, SF3B1 is linked to B-cell chronic lymphocytic leukemia.